Cellomics

Cellomics is a Hong Kong-based biotechnology company specializing in liquid biopsy solutions for early cancer screening and precision oncology. Founded in 2018 as a spin-off from the City University of Hong Kong, the company develops proprietary technologies for circulating tumor cell (CTC) enrichment, digital PCR, and next-generation sequencing. Its product portfolio includes automated CTC sorting systems and diagnostic kits for various cancers, including lung, liver, and breast cancer. Cellomics operates ISO 13485-certified manufacturing facilities and medical laboratories in Hong Kong and the Greater Bay Area. The company aims to transform cancer management through non-invasive, high-sensitivity diagnostic tools.